ライフサイエンスコーパス: minipump

1 icotine free base, 15 to 22 days via osmotic minipump).

2 h-1) or vehicle for 3 weeks by osmotic minipump.

3 almefene or vehicle for 7 days by an osmotic minipump.

4 mice 125 mg/kg of bleomycin via s.c. osmotic minipump.

5 lateral ventricle via the implanted osmotic minipump.

6 lly relevant doses, administered via osmotic minipump.

7 ously by remote activation of an implantable minipump.

8 ation via a subcutaneously implanted osmotic minipump.

9 elivered from a surgically implanted osmotic minipump.

10 re administered exogenously via an implanted minipump.

11 dministered the drug for 3 weeks via osmotic minipump.

12 delivered subcutaneously through an osmotic minipump.

13 or by continuous s.c. infusion from osmotic minipumps.

14 g recombinant IGF-I administered via osmotic minipumps.

15 anterior optic nerve with osmotically driven minipumps.

16 with NOD or vehicle administered via osmotic minipumps.

17 tensinII for 42 days using implanted osmotic minipumps.

18 lied by subcutaneous implantation of osmotic minipumps.

19 to adult male rats for two weeks via osmotic minipumps.

20 trol TAT peptide, or deltaV1-1 using osmotic minipumps.

21 infused with morphine from implanted osmotic minipumps.

22 nfusion from implanted saline-filled osmotic minipumps.

23 ly to male Lewis rats for 6 days using Alzet minipumps.

24 f either saline or Angiotensin II by osmotic minipumps.

25 hicle delivered intra-arterially via osmotic minipumps.

26 inistered to apoE-deficient mice via osmotic minipumps.

27 13 d into Sprague-Dawley rats, using osmotic minipumps.

28 red saline (control) was started using Alzet minipumps.

29 (100 microg x kg(-1) x day(-1)) via osmotic minipumps.

30 area over 2 weeks via chronically implanted minipumps (1-2.5 microgram/d), and the psychomotor stimu

31 In animals exposed to AngII using osmotic minipumps (2.0 mug/kg per min), myocardial CTGF mRNA pea

32 ng II was infused subcutaneously via osmotic minipumps (40 ng/min) for 13 days in two groups (N = 10

33 We modeled 5-HTP SR with minipumps, 5-HTP IR with injections, and chronic SSRI wi

34 ere administered for 2 weeks with an osmotic minipump 72 h after streptozotocin treatment.

35 al of recombinant Emc10 delivered by osmotic minipumps after MI in heart failure-prone FVB/N mice.

36 lution or to the decrease in rabbits without minipumps (analysis of covariance, P = 0.0092).

37 roups received Ang II infusions via a second minipump and drinking water+/-losartan.

38 de (25 mg/kg/day) subcutaneously via osmotic minipump and studied 20-22 h later for rotational behavi

39 ered intracerebroventricularly using osmotic minipumps and then tested the rats during week 2 of ster

40 erm isoprenaline stimulation through osmotic minipumps, and after incubation of rat neonatal cardiomy

41 or vehicle (VEH) was administered by osmotic minipumps, and CNV formation was measured 11 days after

42 fused by intraperitoneally implanted osmotic minipumps, and the resulting circulating concentrations

43 infusing isoproterenol (ISO) for 10 days via minipumps, and then animals were allowed to recover for

44 ith NT-3 or NT-4/5 for 8-35 d via an osmotic minipump attached to its central end at the time of axot

45 subcutaneously to Galpha(q) mice by osmotic minipump beginning on day 12 of pregnancy and continuing

46 An osmotic minipump containing Ang II (1.44 mg/kg per day) was impl

47 went subcutaneous implantation of an osmotic minipump containing either vehicle or leptin at a dose (

48 /HeN mice were implanted subcutaneously with minipumps containing an inhibitor of nitric oxide, NG-ni

49 ague-Dawley rats were implanted with osmotic minipumps containing either vehicle, a cell-permeant pep

50 al rabbits implanted with osmotically driven minipumps containing endothelin-1 (0.1 microgram/day).

51 In the first set, Alzet minipumps containing no PRL, wild-type (WT) PRL, or the

52 On day 18, Alzet minipumps containing no PRL, WT PRL, or S179D PRL were i

53 ing testosterone (T) or nothing, and osmotic minipumps continuously infusing MK-801, a noncompetitive

54 ing, we surgically implanted rats with Alzet minipumps delivering (+)-naltrexone (0, 7.5, 15, 30 mg/k

55 eceptor subunits were implanted with osmotic minipumps delivering 24 mg x kg(-1) x d(-1) nicotine for

56 genous IGF-I concentrations or by implanting minipumps delivering an IGF-1 analogue, R(3)-IGF-1, whic

57 containing cells were implanted with osmotic minipumps delivering AngII (600 ng/kg/min) or saline for

58 anted subcutaneously with pellets or osmotic minipumps delivering morphine displayed time-related tac

59 id adventitia, and 2 days later we implanted minipumps delivering vehicle or Ang II (750 microg/kg pe

60 randomly selected and implanted with osmotic minipumps delivering vehicle or serelaxin for another 4

61 d-induced "pain"); placebo pellets or saline minipumps did not change thresholds.

62 that chronic delivery of (+)-naltrexone via minipumps during the withdrawal phase decreased incubate

63 micromol x kg(-1) x d(-1)) by use of osmotic minipumps (each n=7).

64 on induced by Ang II delivered by an osmotic minipump for 10 days (139 +/- 3 versus 153 +/-2 mmHg in

65 nfusion of anti-NPCT (16 mug per hour) via a minipump for 18 hours.

66 Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake

67 ght external carotid artery using an osmotic minipump for 24 h.

68 y protein transfer into peritoneal cavity by minipump for 4 weeks.

69 ecretin (2.5 nmoles/kg/day by way of osmotic minipumps for 1 week), and biliary mass was evaluated.

70 (1) antagonist Candesartan, s.c. via osmotic minipumps for 14 days, to determine whether peripheral c

71 7beta-estradiol (E2), or vehicle using Alzet minipumps for 2 weeks.

72 hanol (26 nmol microliter-1 h-1) via osmotic minipumps for 3 days.

73 tracerebroventricularly (i.c.v.) via osmotic minipumps for 3 days.

74 6 mg kg(-1) day(-1) ) or vehicle via osmotic minipumps for 3 weeks.

75 or bovine serum albumin (BSA) was infused by minipumps for 7 days to rats and we measured cholangiocy

76 or vehicle (CON) was administered by osmotic minipumps for 8 d to pair-fed adult rats.

77 re administered 25mug/kg/day BPA via osmotic minipumps from gestational day 8 through postnatal day (

78 ed by subcutaneous infusion using an osmotic minipump implanted 3 d before the induction of diabetes

79 odeoxyuridine (BrdU) delivered by an osmotic minipump implanted in the mother; cell birth dates were

80 AngII (60 ng/min) or vehicle via an osmotic minipump implanted subcutaneously in the dorsum of the n

81 ow was determined in two rabbits that had no minipump implants.

82 s after chronic nicotine exposure by osmotic minipump in adult and periadolescent rats.

83 were included to monitor the efficacy of the minipumps in raising plasma leptin in B6 mice.

84 ensitization) or continuously via an osmotic minipump (induces tolerance).

85 s post-lactation were implanted with osmotic minipumps infusing either naltrexone (NTX) (70 microg/h)

86 egnant rats were given nicotine by implanted minipump infusion either from gestational days 4-12 or 4

87 Minipump infusion of angiotensin II to Ren1c-/- mice res

88 ntrols (vehicle, single bolus, or continuous minipump infusion of trophic factor, or killed cell graf

89 poration of 5-bromodeoxyuridine (BrdU; 7-day minipump infusion).

90 d nicotine to adolescent rats via continuous minipump infusions from PN30 to PN47.5, using 6 mg/kg/da

91 o pregnant or adolescent rats via continuous minipump infusions, using dose rates that replicate the

92 In addition, we infused VEGF via minipump into the adult cortex.

93 by implantation of a bacteria-filled osmotic minipump into the peritoneal cavity.

94 nfusion of angiotensin II (AngII) by osmotic minipump into the subcutaneous space of mice at doses ra

95 We infused oxytocin by osmotic minipump into vasopressin-deficient Brattleboro rats for

96 ed Ang II or vehicle for 1 month via osmotic minipumps into mature apoE(-/-) mice.

97 , 7.13, 20.41 and 43.1 mg/kg/day via osmotic minipump or intermittently at 11.32 mg/kg/day via one da

98 er day) by means of an Alzet (Palo Alto, CA) minipump or vehicle [polyethylene glycol (PEG 300)] for

99 y of IL-2 into the mouse brain using osmotic minipumps or injection of mice with recombinant IL-2 pro

100 e, phencyclidine (PCP, 15 mg/kg/d by osmotic minipump), or PCP+glycine (16% by weight diet) intervent

101 as studied by infusing D-AP5 with an osmotic minipump over barrel cortex for 5 d of novel sensory exp

102 ived the vasopressin analog dDAVP by osmotic minipump plus either a daily water load (vasopressin esc

103 angiotensin II and isoproterenol by osmotic minipump produced increases in heart weight (15 and 45%,

104 ed subcutaneously over 22.75 h using osmotic minipumps producing steady state plasma concentrations o

105 infusion of insulin into the CNS via osmotic minipumps reduced the hepatic lipid content as assessed

106 were treated with relaxin (4 mug/h, osmotic minipump), relaxin plus PPARgamma inhibitor GW9662 (10 m

107 o address these issues, we implanted osmotic minipumps subcutaneously to deliver an NMDA receptor ant

108 BL/6 mice were implanted with a subcutaneous minipump that delivered a continuous infusion of secrete

109 s made hypertensive by implanting an osmotic minipump that delivered Ang II (0.7 mg/kg per day).

110 oventricular (i.c.v.) cannula and an osmotic minipump that delivered vehicle or 1.56 ng/h recombinant

111 f rats was implanted with Alzet((R)) osmotic minipumps that continuously released NTX into the latera

112 ion of arginine vasopressin (AVP) by osmotic minipump, the 117-kD band was markedly diminished, where

113 nfusion catheter connected to a subcutaneous minipump, the release of amino acids before and during a

114 ionitrile (BAPN) was administered by osmotic minipump to 38-week-old C57BL/6J male mice for 2 weeks.

115 and insulin was administered via an osmotic minipump to achieve moderate hyperglycemia.

116 Inosine applied with a minipump to the rat sensorimotor cortex stimulated intac

117 am control solution was delivered by osmotic minipump to the retrolaminar region of one optic nerve o

118 Osmotic minipumps to infuse dDAVP, the V2-selective vasopressin

119 Subcutaneous injections of ibuprofen via minipumps to rats with a thoracic spinal cord transectio

120 a continuous infusion with implanted osmotic minipumps, using a dose rate (3-6 mg kg-1 day-1) set to

121 bate, delivered at 37 degrees C from osmotic minipumps, was stable for 8 days as determined by its re

122 Finally, using an osmotic minipump, we infused AS-PKCalpha into mice in which myoc

123 Osmotic minipumps were implanted in pregnant Sprague-Dawley rats

124 Three weeks after lesioning, osmotic minipumps were implanted that released recombinant human

125 yuridine (EdU)-a thymidine analog-containing minipumps were inserted at the time of MI induction.

126 Osmotic minipumps were used to infuse intracerebrally a specific

127 Osmotic minipumps were used to treat normal rats with ET-1 for 5

128 purpose, female mice were infused by osmotic minipumps with a single class II MHC-presented HY peptid

129 Rats were infused intravenously via minipumps with either saline, rat oxyntomodulin (0.47 nm